<<

® PPracticalediatric Pearls From the Cutis Board

Spironolactone for Adult Female

Many cases of acne are hormonal in nature, meaning that they occur in adolescent girls and women and are aggravated by hormonal fluctuations such as those that occur during the or in the setting of underlying hormonal imbalances as seen in polycystic syndrome. For these patients, antihormonal therapy such as is a valid and efficacious option. Herein, initiation and utilization of this is reviewed.

Adam J. Friedman, MD copy What should you do during the first Evaluation of these women with acne for the visit for a patient you may start possibility of hormonal imbalance may be necessary, on spironolactone? with the 2 most common causes of hyperandrogen- Some women will come in asking about spironolac- ismnot being polycystic ovary syndrome and congeni- tone for acne, so it is important to identify potential tal adrenal hyperplasia. The presence of alopecia, candidates for antihormonal therapy: , acanthosis nigricans, or other signs of • Women with acne flares that cycle excess, in combination with dysmenor- with Dorhea or , may be an indication that the • Women with adult-onset acne or persistent- patient has an underlying medical condition that recurrent acne past teenaged years, even needs to be addressed. Blood tests including testos- in the absence of clinical or laboratory signs terone, , follicle-stimulating of , and would be appro- • Women on oral contraceptives (OCs) who priate screening tests and should be performed dur- exhibit moderate to severe acne, especially ing the menstrual period or week prior; the patient with a hormonal patternCUTIS clinically should not be on an OC or have been on one within • Women not responding to conventional ther- the last 6 weeks of testing. apy and not wanting to use oral or Prior to initiating therapy with spironolactone, it is who are not candidates for oral isotretinoin important to establish that there is no history of renal dysfunction; that the patient does not utilize salt substi- tutes, which may contain in place of ; and that the patient is not taking potassium supple- ments, other potassium-sparing (ie, , Dr. Friedman is Associate Professor of Dermatology, Residency ), angiotensin-converting inhibi- Program Director, and Director of Translational Research at the George Washington School of and Health Sciences, tors, or angiotensin II receptor blockers. Washington, DC. Of note, the patient should not be currently or Dr. Friedman is a consultant for Encore Pharmaceuticals; Galderma actively trying to become pregnant. Even though it has Laboratories, LP; Johnson & Johnson Consumer Inc; Liquidia a category C rating, there is substantial theoretical risk Technologies; and Pfizer Inc. He also is on the advisory board and is for teratogenicity, especially in a male (ie, femini- an investigator for Valeant Pharmaceuticals North America, LLC, and is on the advisory board for Johnson & Johnson Consumer Inc. zation of a male fetus). However, there are no reports Correspondence: Adam J. Friedman, MD, Department of linking spironolactone with human congenital defects, Dermatology, 2150 Pennsylvania Ave NW, Washington, DC 20037 and no well-controlled, prospective studies evaluating ([email protected]). spironolactone exposure in pregnant women.

216 CUTIS® WWW.CUTIS.COM Copyright Cutis 2015. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.

Friedman acne pearls.indd 216 10/1/15 2:06 PM Practical Pearls From the Cutis® Board

What does the patient need to know at spironolactone in combination with OCs you can the first visit? kill 3 birds with 1 stone from efficacy (the synergy Because patients have Dr. Internet on call within between the two often allows for lower dosing of spi- seconds on their smartphones and tablets, there ronolactone without compromising impact), contra- are several points I review with patients as a semi- ception prevention, and dysmenorrhea perspectives. preemptive strike. I do offer OCs to eligible patients who are starting Spironolactone is not approved by the US Food on spironolactone. In general, spironolactone can and Drug Administration for the treatment of acne; be used safely in combination with oral , however, it has been used for decades for acne and though oral use should be short-term to even longer for the management of high blood pres- limit rising rates of antimicrobial resistance. Of note, sure (since 1957!). Because it is a potassium-sparing there may be risk for when spironolac- , patients need to be careful not to get too tone is combined with trimethoprim-sulfamethoxazole, much of a good thing (ie, potassium). I counsel so its use should be avoided in this setting. patients on potassium intake, including sources such as diet (ie, fruit/fruit drinks), coconut water How do you keep patients compliant (very popular right now), and over-the-counter with treatment? nutritional supplements. If are playing a notable role in the patient’s Spironolactone is used in varying doses depend- acne, some response is usually noted by even the first ing on the situation (25–200 mg daily), but it is return visit, which I always make for 4 weeks later, important to start with a lower dose and escalate in unlike with other acne treatment regimens, which I a stepwise fashion, if needed, depending on how the usually make for 7 to 8 weeks later. Even though most patient is doing. I usually tell the patient it requires treatments require at least 8 weeks to show any sign at least one boost in the dosage (around 50 mg of improvement,copy even spironolactone at times, close twice daily) to appreciate notable results; however, follow-up allows me to increase the dose, which is often patients will often have some improvement even at needed, or change to another medication if the patient the lowest dose of 25 mg twice daily within 4 weeks is not tolerating it. Given that I stress it will require tak- of treatment initiation, which is when I have them ing notthe medication every day in a consistent fashion to return for reevaluation. allow me to effectively evaluate it, the short time frame Spironolactone will help with acne on the face, between visits also enhances compliance, as it encour- back, and chest. ages the patient to actually take the medication and The majority of sides effects associated withDo spi- incorporate it into her routine. ronolactone are dose dependent; low-dose therapy (25–50 mg daily) generally is well tolerated, and What do you do if patients even 100 mg daily is not problematic in most cases. refuse treatment? Dose-dependent side effects include frequent uri- I always tell my patients they are the captains and nation, menstrual irregularities, tenderness I am helping them navigate through their . and/or enlargement, low , hyperka- I will, however, discuss the chronicity of acne as lemia, and reduced . CUTISOf note, a recent study well as the long-term sequelae of this inflammatory (Plovanich et al) found that the incidence of disease including scarring and postinflammatory pig- hyperkalemia in healthy young women taking spi- ment alteration for which there are no great treat- ronolactone for acne is equivalent to the baseline ments. I also tell them that if there is any issue with rate of hyperkalemia in this specific population. the medication, we simply stop, and the likelihood Therefore, routine potassium monitoring is unnec- for severe adverse events is exceedingly low based on essary for healthy women taking spironolactone for the evidence and anecdotal experience. acne. I tend not to check potassium in these patients unless I head to higher doses due to poor response or SUGGESTED READINGS I am treating female pattern alopecia, which often Plovanich M, Weng QY, Mostaghimi A. Low usefulness of requires higher dosing. potassium monitoring among healthy young women taking Spironolactone has sufficient data to suggest that spironolactone for acne. JAMA Dermatol. 2015;151:941-944. long-term use appears to be safe overall. There was Schmidt TH, Shinkai K. Evidence-based approach to cuta- one long-term study with patients who received neous hyperandrogenism in women. J Am Acad Dermatol. spironolactone for up to 8 years for the treatment of 2015;73:672-690. acne vulgaris (Shaw and White). Shaw JC, White LE. Long-term safety of spironolactone in Spironolactone can be used as monotherapy or in acne: results of an 8-year followup study. J Cutan Med Surg. combination with OCs safely. In fact, by prescribing 2002;6:541-545.

WWW.CUTIS.COM VOLUME 96, OCTOBER 2015 217 Copyright Cutis 2015. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.

Friedman acne pearls.indd 217 10/1/15 2:06 PM